The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...
Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...
The US FDA has approved the first of its kind ketamine-based nasal spray which ... the FDA approved the Johnson & Johnson drug called Spravato (esketamine) to treat some cases of depression ...
Spravato, a newly FDA-approved nasal spray, offers hope for individuals with treatment-resistant depression, a condition ...